Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 476-160-4 | CAS number: 54807-34-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Study period:
- 1991-09-18 to 1991-11-15
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study follows GLP and internationally accepted test method guideline.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 85-1 (Metabolism and Pharmacokinetics)
- Deviations:
- no
- GLP compliance:
- yes
Test material
- Reference substance name:
- 5,5-dimethylhydantoin
- EC Number:
- 201-051-3
- EC Name:
- 5,5-dimethylhydantoin
- Cas Number:
- 77-71-4
- IUPAC Name:
- 5,5-dimethylimidazolidine-2,4-dione
- Reference substance name:
- Dimethylhydantoin
- IUPAC Name:
- Dimethylhydantoin
- Details on test material:
- NON-RADIOLABELLED MATERIAL
- Name of test material: nonradiolabeled DMH
- Physical state: white crystalline solid
- Stability under test conditions: considered stable under conditions of storage and use
- Storage condition of test material: stored in the refrigerator at 5 ºC
RADIOLABELLED MATERIAL
- Name of test material (as cited in study report): radiolabelled DMH or 14C-DMH
Constituent 1
Constituent 2
- Radiolabelling:
- yes
- Remarks:
- DMH radiolabelled with Carbon-14
Test animals
- Species:
- rat
- Strain:
- other: Charles River-CD rats (Crl:CD Br)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Testing lab
- Age at study initiation: 8 weeks
- Weight at study initiation: females: 166-184 g - males: 268-284 g
- Fasting period before study: 18 hours.
- Housing: individual hanging metal cages
- Individual metabolism cages: no
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 2-3 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°F): 63-71 °F
- Humidity (%): 25-72%
- Air changes (per hr): at least seven per hour
- Photoperiod (hrs dark / hrs light): 12 hours dark / 12 hours light
Administration / exposure
- Route of administration:
- other: Oral (gavage) and intraveneous (I.V.)
- Vehicle:
- other: Sterile water for injection USP for oral administration and saline for I.V. administration
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Oral dose:
Radiolabeled dosing solutions were preapred by mixing a weighed amount of nonradiolabeled DMH with an appropriate amount of 14C-DMH in a glass vial. Sterile water for injection, USP was added to acheieve the desired final concentrations. The nonlabeled dosing solution used in the repeated low-dose oral experiment was prepared by mixing a weighed amount of non-radiolabeled DMH with an appropriate volume of sterile water. The dosing solution was made up once to dose on days 1 through 7 and a second time to dose on days 8 through 14.
IV dose:
The dosing solution preparation was identical to the oral dosing solution preparation except normal saline (0.9% Sodium Chloride) was used instead of sterile water.
VEHICLE
- Amount of vehicle: 5 mL of dosing solution per kg/bw for low dose (100 mg/kg) and 10 mL/kg in single oral high-dose group (1000 mg/kg). A dose volume of 2.5 mL/lg for IV administration was used.
- Lot/batch no: Sterile water (McGaw, Inc., Lot No. JDJ039A Exp. 7/91), 0.9% sodium chloride (Kendall McGaw, Lot #JDJ035A)
HOMOGENEITY AND STABILITY OF TEST MATERIAL:
Th radiolabeled purity of the 100 mg/kg and 1000 mg/kg oral dosing solutions was determined by HPLC to be greater than 99% on the day of dosing. The stability of 14C-DMH in corn oil was determined to be at least eight days by HPLC. - Duration and frequency of treatment / exposure:
- Four experiments were conducted as part of the study which involved the administration of 14C-DMH at a single oral dose; at a repeated oral low dose; at a single oral high-dose; and at a single intravenous low-dose.
Rats in the repeat oral low-dose were administered non-radiolabelled DMH daily at a dose level of 100 mg/kg/day for days 1-7 and 80 mg/kg/day for days 8-14 by gavage prior to a single dose of 14C-labelled DMH.
All other regimens were provided as a single dose.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Single oral high dose: 1000 mg/kg
Single oral low dose: 100 mg/kg
Repeated oral low dose: 100 mg/kg (days 1-7) then 80 mg/kg (days 8-15) and radiolabelled material for the last dose only.
Intraveneous (I.V.): 100 mg/kg
- No. of animals per sex per dose / concentration:
- 5/sex/group
- Control animals:
- no
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: urine, faeces, cage washes, blood, gastrointestinal tract (stomach, small intestine, large intestine, GI tract contents), bone, brain, fat, gonads (testes, seminal vesicles, prostate, ovaries, uterus); heart; kidneys; liver; lings; muscle; spleen; pancreas; skin; hair and residual carcass).
- Time and frequency of sampling:
Urine, faeces, and washings of urine/faeces separators were collected at the following intervals: 0-4 , 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours.
Blood, tissues and organs were harvested 7 days (168 h) after administration of 14C-DMH
METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled: urine and faeces
- Time and frequency of sampling: samples were collected over the following time intervals: 0-6, 6-24, 24-48 and 48-72 hours.
- From how many animals: 5/sex
- Method type for identification: HPLC
Results and discussion
- Preliminary studies:
- Prior to undertaking this study, a preliminary study was undertaken to determine if 14C-CO2 would be evolved in the expired air following oral dose administration (BTC project number P01979). No significant amount of 14C-CO2 was evolved.
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Test substance DMH was adsorbed completely and readily.
- Details on distribution in tissues:
- Tissue residues expressed as ppm 14C-DMH equivalents and percent of administered dose were very low and with the exception of the single oral high-dose group, were similar for all dosage regimens. The slightly higher tissue residue levels in a few tissues in the single oral high-dose group were considered to be a reflection of the higher dose administered to the animals in this group.
Only in hair and possibly fat, were residue levels above those found in plasma found with any regularity. The slightly higher residue levels in fat were not of the magnitude to suggest significant bioaccumulation. The residue levels in hair may indicate some preference for 14C-DMH to accumulate in this matrix or may be an artefact of trying to determine 14C residue levels in extremely small samples.
- Details on excretion:
- Regardless of dosing regimes, more than 90% of the dosed radioactivity in both male and female rats was excreted, unchanged, in the urine (90.50-96.25%) while less than 1.37% was excreted in the faeces. Most of the radioactivity recovered in the urine was excreted within the first 12 hours. Urinary half lives were superimposable, with values of 3.0-3.25h (males) and 2.4-2.8 h (females).
Metabolite characterisation studies
- Metabolites identified:
- no
Any other information on results incl. tables
Table 1: Mean total recovery of radioactivity expressed as a percentage of administered dose (%)
|
Males |
Females |
||||||
Dose level |
Single oral low dose |
Single oral high dose |
Repeat oral low dose |
Single IV low dose |
Single oral low dose |
Single oral high dose |
Repeat oral low dose |
Single IV low dose |
Urine
|
94.18
|
90.50
|
95.68
|
95.34
|
93.34
|
93.37
|
96.25
|
93.80
|
Faeces
|
0.74
|
1.00
|
0.88
|
1.23
|
0.72
|
0.76
|
1.37
|
0.66
|
Carcass and tissue |
0.03
|
0.16
|
0.01
|
0.12
|
0.03
|
0.01
|
0.11
|
0.04
|
Total14C
|
94.96
|
91.65
|
96.57
|
96.69
|
94.09
|
94.14
|
97.73
|
94.51
|
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
The data from the study demonstrated that 14C-DMH is well absorbed and rapidly and quantitatively excreted, unchanged, in the urine following oral or intravenous administration. There was no evidence for significant tissue accumulation. - Executive summary:
This study has been performed on DMH (Dimethyl Hydantoin) and has been used for read-across purposes.
The data from the study demonstrated that 14C-DMH is well absorbed and rapidly and quantitatively excreted, unchanged, in the urine following oral or intravenous administration. There was no evidence for significant tissue accumulation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
